United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $593.99, for a total value of $5,642,905.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $192,715,897.57. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Trading Down 0.4%

Shares of United Therapeutics stock traded down $2.35 on Thursday, reaching $593.31. 321,326 shares of the company were exchanged, compared to its average volume of 554,860. The stock has a fifty day moving average price of $538.56 and a 200-day moving average price of $535.20. The firm has a market capitalization of $25.27 billion, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 3.94 and a beta of 0.49. United Therapeutics Corporation has a fifty-two week low of $455.63 and a fifty-two week high of $614.23.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The company had revenue of $832.50 million for the quarter, compared to analysts’ expectations of $781.14 million. During the same period in the prior year, the company earned $7.16 earnings per share. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.90 earnings per share for the current fiscal year.

United Therapeutics announced that its board has initiated a stock buyback program on Thursday, October 22nd that authorizes the company to buy back $2 billion in outstanding shares. This buyback authorization authorizes the biotechnology company to buy up to 8.3% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Arjuna Capital boosted its stake in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after buying an additional 18 shares during the period. Meeder Advisory Services Inc. raised its holdings in shares of United Therapeutics by 3.0% during the third quarter. Meeder Advisory Services Inc. now owns 657 shares of the biotechnology company’s stock worth $356,000 after acquiring an additional 19 shares in the last quarter. Abacus Wealth Partners LLC increased its position in United Therapeutics by 5.6% in the 3rd quarter. Abacus Wealth Partners LLC now owns 396 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 21 shares during the last quarter. Bryn Mawr Trust Advisors LLC raised its stake in shares of United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of United Therapeutics by 2.1% during the 3rd quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company’s stock worth $625,000 after purchasing an additional 24 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics News Roundup

These are some of the UTHR news items that stood out recently:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target, about 11% above the recent trading level. Its forecasts call for EPS of $27.46 in 2026 and $53.67 by 2030, pointing to substantial expected earnings growth. HC Wainwright coverage
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.64 million, and director Christopher Patusky sold 1,210 shares for about $702,000. Insider sales may weigh on sentiment, though neither transaction alone establishes a negative view of the company’s prospects. CEO sale filing Director sale filing
• Negative Sentiment: In its latest reported quarter, UTHR’s EPS of $5.71 fell short of the $6.01 analyst consensus, although revenue of $832.5 million exceeded expectations and rose 4.1% year over year. The earnings miss may temper the positive analyst outlook.

Analyst Upgrades and Downgrades

Several brokerages have commented on UTHR. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a report on Wednesday, October 28th. Leerink Partners upped their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research report on Monday, October 19th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $368.00 price objective on shares of United Therapeutics in a research note on Thursday, October 15th. Morgan Stanley lifted their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Finally, HC Wainwright assumed coverage on shares of United Therapeutics in a research note on Monday. They set a “buy” rating and a $660.00 target price on the stock. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $676.40.

About United Therapeutics

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.